Abstract

Introduction: Delirium occurs frequently in adults undergoing hematopoietic cell transplantation, with significant associated morbidity. Little is known about the burden of delirium in children in the peri-transplant period. This study was designed to determine delirium rates, define risk factors (demographic and treatment related), and establish feasibility of multi-institutional bedside screening for delirium in children undergoing hematopoietic cell transplant.Methods: This is a multi-institutional point prevalence study. All subjects were prospectively screened for delirium twice daily using the Cornell Assessment of Pediatric Delirium over a 10-day period. De-identified data, including basic demographics and daily characteristics, were extracted from the electronic medical record.Results: Eleven North American institutions were included, 106 children were enrolled, and 883 hospital days were captured. Delirium screening was successfully completed on more than 98% of the study days. Forty-eight children (45%) developed delirium over the course of the 10-day study. Children were diagnosed with delirium on 161/883 study days, for an overall delirium rate of 18% per day. Higher delirium rates were noted in children <5 years old (aOR 0.41 for children over 5 years), and in association with specific medications (melatonin, steroids, and tacrolimus).Conclusion: Delirium was a frequent occurrence in our study cohort, with identifiable risk factors. Delirium screening is highly feasible in the pediatric hematopoietic cell transplant patient population. A large-scale prospective longitudinal study following children throughout their transplant course is urgently needed to fully describe the epidemiology of pediatric delirium, explore the effects of delirium on patient outcomes, and establish guidelines to prevent and treat delirium in the peri-transplant period.

Highlights

  • Delirium occurs frequently in adults undergoing hematopoietic cell transplantation, with significant associated morbidity

  • Sites were invited to participate via emails sent to members of the following research consortiums: the hematopoietic cell transplantation (HCT) subgroup of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI), and the Pediatric Bone Marrow Transplant Consortium Supportive Care Strategy Group

  • Over the course of a 10-day period in April 2019, 11 institutions participated in this point prevalence study

Read more

Summary

Introduction

Delirium occurs frequently in adults undergoing hematopoietic cell transplantation, with significant associated morbidity. Delirium is defined as an acute and fluctuating syndrome, and includes altered awareness and cognition It occurs as a result of an underlying medical condition or as a side effect of treatment for that condition [4]. Delirium is a well-known complication of hematopoietic cell transplantation (HCT) in adults, affecting >50% of patients in the 4 weeks after transplant [11, 12]. In these adults, delirium is associated with increased mortality (both in-hospital and up to 5 years after discharge) and substantial morbidity, including increased use of opioid analgesics, increased hospital length of stay, and increased family and healthcare team distress. As a result of this critical knowledge gap, no similar changes have taken place in pediatric HCT programs [18]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call